Table 1.
Knight Alzheimer Disease Research Center (ADRC) participant characteristics
| Group | All | Amyloid | Amyloid+ | p |
|---|---|---|---|---|
| N | 274 | 191 | 83 | |
| Age (years ± SD) | 65 ± 9.0 | 62.3 ± 8.3 | 71.2 ± 7.4 | < 0.0001 |
| Education (years ± SD) | 16.0 ± 2.50 | 16.1 ± 2.41 | 15.8 ± 2.70 | N.S. |
| Sex (n, % Female) | 159, 58% | 116, 61% | 43, 52% | N.S. |
| Race (n, %) | ||||
| Asian | 1, <1% | 1, < 1% | 0, 0% | N.S. |
| Black | 23, 8% | 19, 10% | 4, 5% | N.S. |
| Non-Hispanic White | 250, 91% | 171, 90% | 79, 95% | N.S. |
| APOE ε4 statusa (n, %) | 107, 39% | 56, 29% | 51, 61% | < 0.0001 |
| PET Centiloid (mean ± SD) | 13.3 ± 28.3 | −2.14 ± 5.16 | 46.4 ± 29.4 | < 0.0001 |
| CSF Aβ42 (pg/mL) | 1330 ± 620 | 1600 ± 540 | 730 ± 260 | < 0.0001 |
| CSF t-tau (pg/mL) | 229 ± 106 | 188 ± 64.1 | 321 ± 124 | < 0.0001 |
| CSF ptau181 (pg/mL) | 21.2 ± 11.8 | 16.5 ± 5.71 | 32.1 ± 14.6 | < 0.0001 |
| CSF SNAP-25 (pg/mL) | 5.03 ± 1.72 | 4.66 ± 1.56 | 5.9 ± 1.76 | < 0.0001 |
| CSF Ng (pg/mL) | 2080 ± 1120 | 1770 ± 880 | 2790 ± 1290 | < 0.0001 |
| CSF NfL (pg/mL) | 1390 ± 690 | 1230 ± 620 | 1750 ± 690 | < 0.0001 |
| Group | APOE ε4− | APOE ε4+ | p | |
| n | 167 | 107 | ||
| Age (years ± SD) | 64.9 ± 8.5 | 65.2 ± 9.78 | N.S. | |
| Education (years ± SD) | 16 ± 2.5 | 16 ± 2.58 | N.S. | |
| Sex (n, % Female) | 101, 60% | 58, 54% | N.S. | |
| Race (n, %) | ||||
| Asian | 1, 1% | 0, 0% | N.S. | |
| Black | 15, 9% | 8, 7% | N.S. | |
| Non-Hispanic White | 151, 90% | 99, 93% | N.S. | |
| Amyloid statusa (n, %) | 32, 19% | 51, 48% | < 0.0001 | |
| PET Centiloid (mean ± SD)b | 7.82 ± 26.0 | 22.9 ± 30.0 | 0.0004 | |
| CSF Aβ42 (pg/mL) | 1460 ± 630 | 1130 ± 550 | < 0.0001 | |
| CSF t-tau (pg/mL) | 216 ± 100 | 249 ± 109 | 0.01 | |
| CSF ptau181 (pg/mL) | 19.8 ± 11 | 23.5 ± 12 | 0.01 | |
| CSF SNAP-25 (pg/mL) | 4.44 ± 1.4 | 5.95 ± 1.72 | < 0.0001 | |
| CSF Ng (pg/mL) | 1970 ± 1070 | 2250 ± 1190 | 0.04 | |
| CSF NfL (pg/mL) | 1340 ± 680 | 1470 ± 690 | N.S. |
Demographic comparison of amyloid-positive and amyloid-negativea groups, and APOE ε4 carriers and noncarriers. P values reflect between group comparisons using unpaired t-tests for continuous variables and chi-square tests for categorical variables. All participants are CDR 0.
a
Amyloid-negative if CSF ptau181/Aβ42 < 0.0198; Amyloid-positive if CSF ptau181/Aβ42 ≥0.0198 (Schindler et al., 2018).
b
Average across the subset of participants who had PET Centiloid data; all participants underwent CSF testing.